BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35984905)

  • 1. Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.
    Poplineau M; Platet N; Mazuel A; Hérault L; N'Guyen L; Koide S; Nakajima-Takagi Y; Kuribayashi W; Carbuccia N; Haboub L; Vernerey J; Oshima M; Birnbaum D; Iwama A; Duprez E
    Blood; 2022 Dec; 140(22):2358-2370. PubMed ID: 35984905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.
    Coccaro N; Zagaria A; Orsini P; Anelli L; Tota G; Casieri P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Mestice A; Delia M; Brunetti C; Specchia G; Albano F
    Hum Pathol; 2018 Oct; 80():82-86. PubMed ID: 29530751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
    Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
    He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
    Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
    Ruthardt M; Testa U; Nervi C; Ferrucci PF; Grignani F; Puccetti E; Grignani F; Peschle C; Pelicci PG
    Mol Cell Biol; 1997 Aug; 17(8):4859-69. PubMed ID: 9234742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment.
    Park DJ; Chumakov AM; Vuong PT; Chih DY; Gombart AF; Miller WH; Koeffler HP
    J Clin Invest; 1999 May; 103(10):1399-408. PubMed ID: 10330422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.
    Nichol JN; Galbraith MD; Kleinman CL; Espinosa JM; Miller WH
    Cell Rep; 2016 Mar; 14(12):2938-49. PubMed ID: 26997274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia.
    Chen Z; Tong JH; Dong S; Zhu J; Wang ZY; Chen SJ
    Genes Chromosomes Cancer; 1996 Mar; 15(3):147-56. PubMed ID: 8721678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells.
    Witcher M; Shiu HY; Guo Q; Miller WH
    Blood; 2004 Nov; 104(10):3335-42. PubMed ID: 15256426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.
    Guidez F; Parks S; Wong H; Jovanovic JV; Mays A; Gilkes AF; Mills KI; Guillemin MC; Hobbs RM; Pandolfi PP; de Thé H; Solomon E; Grimwade D
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18694-9. PubMed ID: 18000064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent alterations of the RAR alpha gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines.
    Morosetti R; Grignani F; Liberatore C; Pelicci PG; Schiller GJ; Kizaki M; Bartram CR; Miller CW; Koeffler HP
    Blood; 1996 May; 87(10):4399-403. PubMed ID: 8639801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.
    Redner RL; Rush EA; Faas S; Rudert WA; Corey SJ
    Blood; 1996 Feb; 87(3):882-6. PubMed ID: 8562957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.
    Zhang JW; Wang JY; Chen SJ; Chen Z
    J Biosci; 2000 Sep; 25(3):275-84. PubMed ID: 11022230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
    Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
    Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation response of acute promyelocytic leukemia cells and PML/RARa leukemogenic activity studies by real-time RT-PCR.
    Caprodossi S; Pedinotti M; Amantini C; Santoni G; Minucci S; Pelicci PG; Fanelli M
    Mol Biotechnol; 2005 Jul; 30(3):231-8. PubMed ID: 15988048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent
    Osumi T; Tsujimoto SI; Tamura M; Uchiyama M; Nakabayashi K; Okamura K; Yoshida M; Tomizawa D; Watanabe A; Takahashi H; Hori T; Yamamoto S; Hamamoto K; Migita M; Ogata-Kawata H; Uchiyama T; Kizawa H; Ueno-Yokohata H; Shirai R; Seki M; Ohki K; Takita J; Inukai T; Ogawa S; Kitamura T; Matsumoto K; Hata K; Kiyokawa N; Goyama S; Kato M
    Cancer Res; 2018 Aug; 78(16):4452-4458. PubMed ID: 29921692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.